AQUAテクノロジーに関する文献(癌疾患領域別)と臨床試験情報のご紹介
Breast Cancer
Dana Faratian, Alexey Goltsov, Galina Lebedeva, Anatoly Sorokin, Stuart Moodie, Peter Mullen, Charlene Kay, In Hwa Um, Simon Langdon, Igor Goryanin, and David J. Harrison. Systems Biology Reveals New Strategies for Personalizing Cancer Medicine and Confirms the Role of PTEN in Resistance to Trastuzumab. AACR Journals Systems Biology and Emerging Technologies, 2009.
Wang Y, Dean JL, Millar EK, Tran TH, McNeil CM, Burd CJ, Henshall SM, Utama FE, Witkiewicz A, Rui H, Sutherland RL, Knudsen KE, Knudsen ES. Thomas Jefferson University. Cyclin D1b Is Aberrantly Regulated in Response to Therapeutic Challenge and Promotes Resistance to Estrogen Antagonists Cancer Research 68, 5628-5638. 2008.
Lindsay J, Jiao X, Sakamaki T, Casimiro MC, Shirley LA, Tran TH , Ju X, Liu M, Li Z, Wang C, Katiyar S, Rao M, Allen KG, Glazer RI, Ge C, Stanley P, Lisanti MP, Rui H and Pestell RG. ErbB2 induces Notch1 activity and function in breast cancer cells. Clinical and Translational Science 2009.
Harigopal M, Heymann J, Ghosh S, Anagnostou V, Camp RL, Rimm DL. Estrogen Receptor Co-Activator (AIB1) Protein Expression by Automated Quantitative Analysis (AQUA) in a Breast Cancer Tissue Microarray and Association with Patient Outcome Breast Cancer Research and Treatment 2008.
Nadler Y, Camp RL, Gitnane JM, Moeder C, Rimm DL, Kluger HM, Kluger Y. Expression Patterns and Prognostic Value of Bag-1 and Bcl-2 in Breast Cancer Breast Cancer Res. 2008;10(2):R35. 2008.
Plotnikov A, Li Y, Tran TH, Tang W, Palazzo JP, Rui H, Fuchs SY. Oncogene-Mediated Inhibition of Glycogen Synthase Kinase 3 Beta Impairs Degradation of Prolactin Receptor. Cancer Res. 2008; 68(5):1354-61
Moeder CB, Giltnane JM, Harigopal M, Molinaro A, Robinson A, Gelmon K, Huntsman D, Camp RL, Rimm DL. Quantitative Justification of the Change from 10% to 30% for Human Epidermal Growth Factor Receptor 2 Scoring in the American Society of Clinical Oncology/College of American Pathologists Guidelines: Tumor Heterogeneity in Breast Cancer and its Implications for Tissue Microarray Based Assessment of Outcome. J Clin Oncol. 2007; 25(34):5418-25.
Sherman ME, Rimm DL, Yang XR, Chatterjee N, Brinton LA, Lissowska J, Peplonska B, Szeszenia-Dabrowska N, Zatonski W, Cartun R, Mandich D, Rymkiewicz G, Ligaj M, Lukaszek S, Kordek R, Kalaylioglu Z, Harigopal M, Charrette L, Falk RT, Richesson D, Anderson WF, Hewitt SM, Garcia-Closas M. Variation in breast cancer hormone receptor and HER2 levels by etiologic factors: A population-based analysis. International Journal of Cancer. 121(5): 1079-85 2007 Sep
Giltnane JM, Rydén L, Cregger M, Bendahl PO, Jirström K, Rimm DL. Quantitative measurement of epidermal growth factor receptor is a negative predictive factor for tamoxifen response in hormone receptor positive premenopausal breast cancer. Journal of Clinical Oncology 25(21): 3007-3014. 2007.
Rimm DL, Giltnane JM, Moeder C, Harigopal M, Chung GG, Camp RL, Burtness B. Bimodal population or pathologist artifact? J Clin Oncol.10;25(17):2487-8.
Zerkowski MP, Camp RL, Burtness BA, Rimm DL, Chung GG. Quantitative Analysis of Breast Cancer Tissue Microarrays Shows High Cox-2 Expression Is Associated with Poor Outcome. Cancer Investigation 2007:25:1, 19 - 26
Chung GG, Zerkowski MP, Ghosh S, Camp RL, Rimm DL. Quantitative analysis of estrogen receptor heterogeneity in breast cancer. Laboratory Investigation 87(7): 662-669. 2007
Pick E, Kluger Y, Giltnane JM, Moeder C, Camp RL, Rimm DL, Kluger HM. NA Yale University. High HSP90 expression is associated with decreased survival in breast cancer. Cancer Research 67(7):2932-7. 2007.
Chung GG, Zerkowski MP, Ghosh S, Camp RL, Rimm DL. Quantitative analysis of estrogen receptor heterogeneity in breast cancer Laboratory Investigation 10.1038/labinvest.3700543, 2007
Pozner-Moulis S, Cregger M, Camp RL, Rimm DL. Antibody validation by quantitative analysis of protein expression using expression of Met in breast cancer as a model Laboratory Invetigation (2007) 1-10 0023-6837/07, 2007
Dolled-Filhart M, Rydén L, Cregger M, Jirström K, Harigopal M, Camp RL, Rimm DL. Classification of Breast Cancer Using Genetic Algorithms and
TissueMicroarrays. Clinical Cancer Research 12(21): 6459-6468, 2006.
Dolled-Filhart M, McCabe A, Giltnane J, Cregger M, Camp RL, Rimm DL. Quantitative In Situ Analysis of Beta-Catenin Expression in Breast Cancer Shows Decreased Expression is Associated With Poor Outcome. Cancer Research, 66(10): 5487-5494, 2006.
McCabe A, Dolled-Filhart M, Camp RL, Rimm DL. Automated Quantitative Analysis (AQUA) of In Situ Protein Expression, Antibody Concentration, and Prognosis. Journal of the National Cancer Institute 97(24): 1808-1815, 2005.
Siddiqui S, Pawelek J, Handerson T, Lin C-Y, Dickson RB, Rimm DL, Camp RL. Coexpression of Beta-1,6-N-Acetylglucosaminyltransferase V Glycoprotein Substrates Defines Aggressive Breast Cancers with Poor Outcome. Cancer Epidemiology Biomarkers & Prevention14(11): 2517-2523, 2005.
Kluger HM, Chelouche Lev D, Kluger Y, McCarthy MM, Kiriakova G, Camp RL, Rimm DL, Price JE. Using a Xenograft Model of Human Breast Cancer Metastasis to Find Genes Associated With Clinically Aggressive Disease. Cancer Research 65: 5578-5587, July 1, 2005.
McCarthy MM, Sznol M, DiVito KA, Camp RL, Rimm DL, Kluger HM. Evaluating the Expression and Prognostic Value of TRAIL-R1 and TRAIL-R2 in Breast Cancer. Clinical Cancer Research 11(14): 5188-5194, 2005.
Harigopal M, Berger AJ, Camp RL, Rimm DL, Kluger HM. Automated Quantitative Analysis of E-Cadherin Expression in Lymph Node Metastases is Predictive of Survival in Invasive Ductal Breast Cancer. Clinical Cancer Research 11: 4083-4089, 2005.
Camp RL, Dolled-Filhart M, Rimm DL. X-Tile: A New Bio-Informatics Tool for Biomarker Assessment and Outcome-Based Cut-Point Optimization. Clinical Cancer Research 10: 7252-7259, 2004.
DiVito KA, Charette LA, Rimm DL, Camp RL. Long-Term Preservation of Antigenicity on Tissue Microarrays. Laboratory Investigation 84(8): 1071-1078, 2004.
Camp RL, Dolled-Filhart M, King BL, Rimm DL. Quantitative Analysis of Breast Cancer Tissue Microarrays Shows That Both High and Normal Levels of HER2 Expression Are Associated with Poor Outcome. Cancer Research 63: 1445-1448, 2003
Kolesar J, Huang W, Eickhoff J, Hahn K, Alberti D, Attia S, Schelman W, Holen K, Traynor A and Wilding G. Evaluation of mRNA by Q-RTPCR and Protein Expression by AQUA of M2 Sub-unit of Ribonucleotide Reductase (RRM2) in Human Tumors. Appl Immunohistochem Mol Morphol. 2009;17(1):23-30.
Colon Cancer
Yoo PS, Sullivan CA, Kiang S, Gao W, Uchio EM, Chung GG, Cha CH. Tissue microarray analysis of 560 patients with colorectal adenocarcinoma: high expression of HuR predicts poor survival. Ann Surg Oncol. 2009 16(1):200-7.
Camp RL, Chung GG, Rimm DL. Automated Subcellular Localization and Quantification of Protein Expression in Tissue Microarrays. Nature Medicine 8(11): 1323-1327, 2002.
Gastric Cancer
Kidd M, Modlin IM, Shapiro MD, Camp RL, Mane SM, Usinger W, Murren JR. CTGF, Intestinal Stellate Cells and Carcinoid Fibrogenesis. World J Gastroenterol. 2007 21;13(39):5208-16.
Kidd, M. Modlin IM, Mane SM, Camp RL, Eick G, Latich I. The Role of Genetic Markers—NAP1L1, MAGE-D2, and MTA1—In Defining Small-Intestinal Carcinoid Neoplasia. Annals of Surgical Oncology 13(2): 253-262, 2006.
Kidd M, Modlin IM, Mane SM, Camp RL, Eick GN, Latich I, Zikusoka MN. Utility of Molecular Genetic Signatures in the Delineation of Gastric Neoplasia. Cancer 106(7):1480-1488, 2006.
Kidd M, Eick G, Shapiro MD, Camp RL, Mane SM, Modlin IM. Microsatellite Instability and Gene Mutations in Transforming Growth Factor-Beta Type II Receptor are Absent in Small Bowel Carcinoid Tumors. Cancer 103(2): 229-236, 2005.
Head and Neck Cancer
Weinberger PM, Yu Z, Haffty BG, Kowalski D, Harigopal M, Brandsma J, Sasaki C, Joe J, Camp RL, Rimm DL, Psyrri A. Molecular Classification Identifies a Subset of Human Papillomavirus-Associated Oropharyngeal Cancers With Favorable Prognosis. Journal of Clinical Oncology 24(5): 736-747, 2006.
Psyrri A, Yu Z, Weinberger PM, Sasaki C, Haffty B, Camp R, Rimm D, Burtness BA. Quantitative Determination of Nuclear and Cytoplasmic Epidermal Growth Factor Receptor Expression in Oropharyngeal Squamous Cell Cancer by Using Automated Quantitative Analysis. Clinical Cancer Research 11(16): 5856-5862,2005.
Yu Z, Weinberger PM, Provost E, Haffty BG, Sasaki C, Joe J, Camp RL, Rimm DL, Psyrri A. Beta-Catenin Functions Mainly as an Adhesion Molecule in Patients With Squamous Cell Cancer of the Head and Neck. Clinical Cancer Research 11: 2471-2477, 2005.
Yu Z, Weinberger PM, Haffty BG, Sasaki C, Zerillo C, Joe J, Kowalski D, Dziura J, Camp RL, Rimm DL, Psyrri A. Cyclin D1 is a Valuable Prognostic Marker in Oropharyngeal Squamous Cell Carcinoma. Clinical Cancer Research 11:1160-1166, 2005.
Lung Cancer
Zheng Z, Li X, Schell MJ, Chen T, Boulware D, Robinson L, Sommers E, Bepler G. Thymidylate Synthase in Situ Protein Expression and Survival in Stage I Nonsmall-Cell Lung Cancer Cancer. 2008;112(12):2765-73.
Gazdar AF. DNA repair and survival in lung cancer--the two faces of Janus. New England Journal of Medicine.356(8):771-3, 2007
Zheng Z, Chen T, Li X, Haura E, Sharma A, Bepler G. DNA synthesis and repair genes RRM1 and ERCC1 in lung cancer. New England Journal of Medicine 356(8):800-8, 2007.
Giltnane JM, Murren JR, Rimm DL, King BL. AQUA and FISH Analysis of HER-2/Neu Expression and Amplification in a Small Cell Lung Carcinoma Tissue Microarray. Histopathology 49: 161-169, 2006.
Melanoma
Rothberg BE, Moeder CB, Kluger H, Halaban R, Elder DE, Murphy GF, Lazar A, Prieto V, Duncan LM, Rimm DL. Nuclear to non-nuclear Pmel17/gp100 expression (HMB45 staining) as a discriminator between benign and malignant melanocytic lesions Mod Pathol. 2008
Kreizenbeck GM, Berger AJ, Subtil A, Rimm DL, Gould Rothberg BE. Prognostic Significance of Cadherin-Based Adhesion Molecules in Cutaneous Malignant Melanoma Cancer Epidemiol Biomarkers Prev. 2008 (4):949-58.
Shields JM, Thomas NE, Cregger M, Berger AJ, Leslie M, Torrice C, Hao H, Penland S, Arbiser J, Scott G, Zhou T, Bar-Eli M, Bear JE, Der CJ, Kaufmann WK, Rimm DL, Sharpless NE Lack of Extracellular Signal-Regulated Kinase Mitogen-Activated Protein Kinase Signaling Shows a New Type of Melanoma Cancer Research 67(4): 1502-1512, 2007
Kluger HM, McCarthy MM, Alvero AB, Sznol M, Ariyan S, Camp RL, Rimm DL, Mor G The X-linked Inhibitor of Apoptosis Protein (XIAP) is Up-regulated in Metastatic Melanoma, and XIAP Cleavage by Phenoxodiol is Associated with Carboplatin Sensitization Journal of Translational Medicine 2007, 5:6 10.1186/1479-5876-5-6, 2007
McCarthy MM, DiVito KA, Sznol M, Kovacs D, Halaban R, Berger AJ, Flaherty KT, Camp RL, Lazova R, Rimm DL, Kluger HM. Expression of Tumor Necrosis Factor-Related Apoptosis-Inducing Ligand Receptors 1 and 2 in Melanoma. Clinical Cancer Research 12(12): 3856-3863, 2006.
Berger AJ, Davis DW, Tellez C, Prieto VG, Gershenwald JE, Johnson MM, Rimm DL, Bar-Eli M. Automated Quantitative Analysis of Activator Protein-2-Alpha Subcellular Expression In Melanoma Tissue Microarrays Correlates With Survival Prediction. Cancer Research 65(23):11185-11192, 2005.
Merlino G. Cancer biology: the weakest link? Nature. 2005; 436(7047):33-5.
Garraway LA, Widlund HR, Rubin MA, Getz G, Berger AJ, Ramaswamy S, Beroukhim R, Milner DA, Granter SR, Du J, Lee C, Wagner SN, Li C, Golub TR, Rimm DL, Meyerson ML, Fisher DE, Sellers WR. Integrative Genomic Analyses Identify MITF as a Lineage Survival Oncogene Amplified in Malignant Melanoma. Nature 436: 117-122, 2005.
DiVito KA, Berger AJ, Camp RL, Dolled-Filhart M, Rimm DL, Kluger HM. Automated Quantitative Analysis of Tissue Microarrays Reveals an Association Between High Bcl-2 Expression and Improved Outcome in Melanoma. Cancer Research 64: 8773-8777, 2004.
Berger AJ, Camp RL, DiVito KA, Kluger HM, Halaban R, Rimm DL. Automated Quantitative Analysis of HDM2 Expression in Malignant Melanoma Shows Association With Early-Stage Disease and Improved Outcome. Cancer Research 64: 8767-8772, 2004.
Ovarian Cancer
Psyrri A, Kountourakis P, Scorilas A, Markakis S, Camp R, Kowalski D, Diamandis EP, Dimopoulos MA. Human tissue kallikrein 7, a novel biomarker for advanced ovarian carcinoma using a novel in situ quantitative method of protein expression Ann Oncol. 2008 (7):1271-7.
Psyrri A, Kountourakis P, Yu Z, Papadimitriou C, Markakis S, Camp RL, Economopoulos T, Dimopoulos MA Analysis of p53 Protein Expression Levels on Ovarian Cancer Tissue Microarray using Automated Quantitative Analysis Elucidates Prognostic Patient Subsets Annals of Oncology 10.1093/annonc/mdl479, 2007
Bamias A, Yu Z, Weinberger PM, Markakis S, Kowalski D, Camp RL, Rimm DL, Dimopoulus MA, Psyrri A. Automated Quantitative Analysis of DCC Tumor Suppressor Protein in Ovarian Cancer Tissue Microarray shows Association with β-catenin Levels and Outcome in Patients with Epithelial Ovarian Cancer. Annals of Oncology 10.1093/annonc/mdl310, 2006.
Psyrri A, Yu Z, Bamias A, Weinberger PM, Markakis S, Kowalski D, Camp RL, Rimm DL, Dimopoulos MA. Evaluation of the Prognostic Value of Cellular Inhibitor of Apoptosis Protein in Epithelial Ovarian Cancer Using Automated Quantitative Protein Analysis. Cancer Epidemiology Biomarkers & Prevention15(6): 1179-1183, 2006.
Psyrri A, Kassar M, Yu Z, Bamias A, Weinberger PM, Markakis S, Kowalski D, Camp RL, Rimm DL, Dimopoulos MA. Effect of Epidermal Growth Factor Receptor Expression Level on Survival in Patients With Epithelial Ovarian Cancer. Clinical Cancer Research 11(24): 8637-8643, 2005.
Psyrri A, Bamias A, Yu Z, Weinberger PM, Kassar M, Markakis S, Kowalski D, Efstathiou E, Camp RL, Rimm DL, Dimopoulos MA. Subcellular Localization and Protein Levels of Cyclin-Dependent Kinase Inhibitor P27 Independently Predict for Survival in Epithelial Ovarian Cancer. Clinical Cancer Research 11(23): 8384-8390, 2005.
Pancreatic Cancer
Attia S, Kolesar J, Mahoney MR, Pitot HC, Laheru D, Heun J, Huang W, Eickhoff J, Erlichman C, Holen KD. A phase 2 consortium (P2C) trial of 3-aminopyridine-2-carboxaldehyde thiosemicarbazone (3-AP) for advanced adenocarcinoma of the pancreas Invest New Drugs. (4):369-79. 2008.
Chung GG, Yoon HH, Zerkowski MP, Ghosh S, Thomas L, Harigopal M, Charette LA, Salem RR, Camp RL, Rimm DL, Burtness BA. Vascular Endothelial Growth Factor, FLT-1, and FLK-1 Analysis in a Pancreatic Cancer Tissue Microarray. Cancer 106(8): 1677-1684, 2006.
Prostate Cancer
Rubin MA, Zerkowski MP, Camp RL, Kuefer R, Hofer MD, Chinnaiyan AM, Rimm DL. Quantitative Determination of Expression of the Prostate Cancer Protein alpha-Methylacyl-CoA Racemase Using Automated Quantitative Analysis (AQUA). American Journal of Pathology 164(3): 831-840, 2004.
Mertz KD, Demichelis F, Kim R, Schraml P, Storz M, Diener PA, Moch H, Rubin MA. Automated Immunofluorescence Analysis Defines Microvessel Area as a Prognostic Parameter in Clear Cell Renal Cell Cancer, Human Pathology 2007 38, 1454-1462
Methods & Reviews
Dana Faratian, Robert G. Clyde, John W. Crawford and David J. Harrison. Systems pathology—taking molecular pathology into a new dimension. Nature Reviews Clinical Oncology 2009.
Rimm, DL. What Brown Cannot Do for You. Nature Biotechnology 24(8): 914-916, 2006.
Dolled-Filhart MP, Rimm DL, Stroobant P. Quantitative In Situ Cancer Proteomics: Molecular Pathology Comes of Age With Automated Tissue Microarray Analysis. Personalized Medicine 2(4): 291-300, 2005.
Henson DE. Back to the Drawing Board on Immunohistochemistry and Predictive Factors. Journal of the National Cancer Institute 97(24): 1796-1797, 2005.
Chiriboga L, Osman I, Mikhail M, Lau C. Tissue Microarrays, Tread Carefully. Laboratory Investigation 84: 1677, 2004.
Clinical Trial
Protein Expression in Predicting Response to Treatment Using Tumor Tissue Samples From Women With Stage I, Stage II, or Stage IIIA Breast
Cancer Treated on Clinical Trial SWOG-9313.
Study of Tissue and Blood Samples From Patients With Recurrent Prostate
Cancer Who Received Lapatinib on Clinical Trial ECOG-E5803.
